NCT05240807Completed
Clinical Impact of Cardiac Photon-Counting Detector CT
Comprehensive Characterization of Coronary Atherosclerotic Disease Using Photon-counting Detector Dual-source CT and Its Impact on Patient Management
Source: ClinicalTrials.gov · Last updated 12 Jun 2026
Brief summary (registry, in English)
The purpose of this research trial is to determine whether images taken using a Photon Counting Detector CT scanner (PCD-CT) provide clinically important information about the severity of suspected coronary artery disease and perfusion defects compared to traditional Energy Integrating Detector CT (EID-CT) and nuclear medicine cardiac stress tests.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 276 (actual)
- First submitted
- 14 Jan 2022
- Start date
- 24 Aug 2022
- Primary completion date
- 19 Feb 2026
- Lead sponsor
- Mayo Clinic
- Diseases
- Coronary artery disease
- NCT number
- NCT05240807
What you commit to
- Study type: Interventional
- Participants enrolled: 276
- From 24 Aug 2022 to the primary completion date, 19 Feb 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- History of prior moderate or severe contrast reaction includes: unresponsiveness, severe respiratory distress, convulsions, arrhythmia, cardiopulmonary distress, progressive angioedema, laryngeal edema, dyspnea, bronchospasm, symptomatic tachycardia, symptomatic bradycardia, hypotension, hypertensive crisis.
- Any history of required premedication prior to iodinated contrast administration.
- Active ongoing wheezing or poorly controlled asthma or COPD (hospitalized within last month or receiving treatment for flair within last month).
Other illness
- Patients experiencing atrial fibrillation, premature ventricular contractions or other heart rhythm abnormalities
- Hospitalized patients or patients under care in the Emergency Department
- Specific exclusion criteria only for participation in the cardiac stress test arm of this study (requiring administration of Regadenoson):
- Known hypersensitivity to Regadenoson, Adenosine, or Dipyridamole.
- Currently experiencing unstable coronary syndrome.
- Uncontrollable seizures within the last 3 months
Lab values
- eGFR ≤ 30
Other
- Patients unable to provide written informed consent
- Pregnancy
- Patients that consent to participation but do not undergo their clinically-indicated, contrast-enhanced CT, or nuclear medicine or MR perfusion scanning for any reason (e.g., bad IV, infiltration, reaction, change in indication).
- Anything by mouth within three hours of the examination
- Second (type I or II) or third degree atrioventricular (AV) block or sinus node dysfunction unless patient has functioning artificial pacemaker.
- Ingested greater than 4 oz. of caffeine within the last 12 hours.
Who the study is looking for
- Patients referred for coronary artery cardiac CT imaging or nuclear medicine or MRI cardiac perfusion within the Department of Radiology or Cardiology.
- Patients who are able and willing to sign the informed consent will be enrolled
- Negative pregnancy test if subject is of child-bearing age (females of child-bearing potential will be screened for pregnancy using a urine pregnancy test, which will be administered by the unit study coordinator at no cost to the patient).
Age in the registry: 18 years to 99 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Mayo Clinic Coordinator of this site? Confirm its status | Rochester | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.